Ariavax Overview
- Year Founded
-
2000
- Status
-
Out of Business
- Latest Deal Type
-
Out of Business
Ariavax General Information
Description
Developer of vaccines that are designed to selectively and specifically generate effective antibody-inducing immune responses. The company's vaccines are based on its proprietary peptide chemistry technology, providing users with vaccines that are safer, more stable and less expensive than current vaccines.
Contact Information
Website
www.ariavax.comCorporate Office
- 708 Quince Orchard Road
- Gaithersburg, MD 20878
- United States
Corporate Office
- 708 Quince Orchard Road
- Gaithersburg, MD 20878
- United States
Ariavax Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 01-Jun-2013 | Completed | Out of Business | |||
| 3. Grant | 01-Feb-2009 | Completed | Generating Revenue | |||
| 2. Grant | 01-May-2005 | $218K | Completed | Generating Revenue | ||
| 1. Accelerator/Incubator | Completed | Startup |
Ariavax FAQs
-
When was Ariavax founded?
Ariavax was founded in 2000.
-
Where is Ariavax headquartered?
Ariavax is headquartered in Gaithersburg, MD.
-
What industry is Ariavax in?
Ariavax’s primary industry is Drug Discovery.
-
Is Ariavax a private or public company?
Ariavax is a Private company.
-
What is Ariavax’s current revenue?
The current revenue for Ariavax is .
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
